Targeting the kynurenine pathway-related alterations in alzheimer's disease: A future therapeutic strategy

Imola Plangár, Dénes Zádori, P. Klivényi, J. Toldi, L. Vécsei

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential. Some of the candidates would be those targeting the kynurenine pathway, the neuroactive metabolites of which are surely involved in both neurodegeneration and neuroprotection, mainly in relation with glutamate excitotoxicity and oxidative stress. Both analogs of the neuroprotective kynurenic acid and small molecule enzyme inhibitors preventing the formation of neurotoxic compounds may have potential therapeutic significance. However, there is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.

Original languageEnglish
Pages (from-to)199-209
Number of pages11
JournalJournal of Alzheimer's Disease
Volume24
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2011

Fingerprint

Kynurenine
Alzheimer Disease
Kynurenic Acid
Enzyme Inhibitors
Blood-Brain Barrier
Neurodegenerative Diseases
Biological Availability
Dementia
Glutamic Acid
Oxidative Stress
Theoretical Models
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • animal models
  • kynurenine pathway
  • therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Targeting the kynurenine pathway-related alterations in alzheimer's disease : A future therapeutic strategy. / Plangár, Imola; Zádori, Dénes; Klivényi, P.; Toldi, J.; Vécsei, L.

In: Journal of Alzheimer's Disease, Vol. 24, No. SUPPL. 2, 2011, p. 199-209.

Research output: Contribution to journalArticle

@article{de75fe24480d458d88b27d29ab358d56,
title = "Targeting the kynurenine pathway-related alterations in alzheimer's disease: A future therapeutic strategy",
abstract = "Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential. Some of the candidates would be those targeting the kynurenine pathway, the neuroactive metabolites of which are surely involved in both neurodegeneration and neuroprotection, mainly in relation with glutamate excitotoxicity and oxidative stress. Both analogs of the neuroprotective kynurenic acid and small molecule enzyme inhibitors preventing the formation of neurotoxic compounds may have potential therapeutic significance. However, there is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.",
keywords = "Alzheimer's disease, animal models, kynurenine pathway, therapy",
author = "Imola Plang{\'a}r and D{\'e}nes Z{\'a}dori and P. Kliv{\'e}nyi and J. Toldi and L. V{\'e}csei",
year = "2011",
doi = "10.3233/JAD-2011-110131",
language = "English",
volume = "24",
pages = "199--209",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Targeting the kynurenine pathway-related alterations in alzheimer's disease

T2 - A future therapeutic strategy

AU - Plangár, Imola

AU - Zádori, Dénes

AU - Klivényi, P.

AU - Toldi, J.

AU - Vécsei, L.

PY - 2011

Y1 - 2011

N2 - Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential. Some of the candidates would be those targeting the kynurenine pathway, the neuroactive metabolites of which are surely involved in both neurodegeneration and neuroprotection, mainly in relation with glutamate excitotoxicity and oxidative stress. Both analogs of the neuroprotective kynurenic acid and small molecule enzyme inhibitors preventing the formation of neurotoxic compounds may have potential therapeutic significance. However, there is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.

AB - Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential. Some of the candidates would be those targeting the kynurenine pathway, the neuroactive metabolites of which are surely involved in both neurodegeneration and neuroprotection, mainly in relation with glutamate excitotoxicity and oxidative stress. Both analogs of the neuroprotective kynurenic acid and small molecule enzyme inhibitors preventing the formation of neurotoxic compounds may have potential therapeutic significance. However, there is a great need for new strategies to improve efficacy, transport across the blood-brain barrier and bioavailability, naturally with simultaneous minimization of the adverse side-effects.

KW - Alzheimer's disease

KW - animal models

KW - kynurenine pathway

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=79955643831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955643831&partnerID=8YFLogxK

U2 - 10.3233/JAD-2011-110131

DO - 10.3233/JAD-2011-110131

M3 - Article

C2 - 21441658

AN - SCOPUS:79955643831

VL - 24

SP - 199

EP - 209

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - SUPPL. 2

ER -